Archive for the ‘Site Default’ Category
Replacing FSX72T12/UVB/HO (7RA-072) with UVB Narrow Band TL01 Lamps
Many people ask about replacing FSX72T12/UVB/HO (7RA-072) lamps in older National Biological Corporation Panosol II (UVB604) units. It’s a fairly easy job to do. We do supply instructions on how to install UVB NB TL100W/01 lamps in the older systems at time of shipment. All the customer need do is order lamps, provide us with the serial number of the UVB604 that the lamps will be installed in and we will ensure that the FDA records are updated to reflect hat the Panolsol II unit with that serial number has been upgraded to now use UVB Narrowband Lamps.
Best thing to do is email us (support@amjo.net) or give us a call 513-942-2770 and we can get the ball rolling for you.
UVA/UVA1 phototherapy and PUVA photochemotherapy…
UVA/UVA1 phototherapy and PUVA photochemotherapy in connective tissue diseases and related disorders: a research based review.
Breuckmann F, Gambichler T, Altmeyer P, Kreuter A.
Department of Dermatology, Ruhr-University Bochum, 44791 Bochum, Germany. Frank.Breuckmann@ruhr-uni-bochum.de.
BACKGROUND: Broad-band UVA, long-wave UVA1 and PUVA treatment have been described as an alternative/adjunct therapeutic option in a number of inflammatory and malignant skin diseases. Nevertheless, controlled studies investigating the efficacy of UVA irradiation in connective tissue diseases and related disorders are rare.
METHODS: Searching the PubMed database the current article systematically reviews established and innovative therapeutic approaches of broad-band UVA irradiation, UVA1 phototherapy and PUVA photochemotherapy in a variety of different connective tissue disorders.
RESULTS: Potential pathways include immunomodulation of inflammation, induction of collagenases and initiation of apoptosis. Even though holding the risk of carcinogenesis, photoaging or UV-induced exacerbation, UVA phototherapy seems to exhibit a tolerable risk/benefit ratio at least in systemic sclerosis, localized scleroderma, extragenital lichen sclerosus et atrophicus, sclerodermoid graft-versus-host disease, lupus erythematosus and a number of sclerotic rarities.
CONCLUSIONS: Based on the data retrieved from the literature, therapeutic UVA exposure seems to be effective in connective tissue diseases and related disorders. However, more controlled investigations are needed in order to establish a clear-cut catalogue of indications.
Original PubMed Link << Click Here >>
Ray Boissy Receives Award
A friend and colleague of mine received “the Achievement Award from the American Skin Association (ASA) for his work studying vitiligo and pigment cell biology.”
Ray Boissy chairs the National Vitiligo Foundation (www.nvfi.org) which is now based here in Cincinnati. The announcement was made yesterday in the University of Cincinnati’s Deans List publication.
The announcement reads:
See http://healthnews.uc.edu/publications/deanslist/?/8616/
Raymond Boissy, PhD, professor of dermatology and cell biology, has received a 2009 Achievement Award from the American Skin Association (ASA) for his work studying vitiligo and pigment cell biology. Boissy was recognized for his contributions to the scientific understanding of the skin disorder, which causes white patches on the skin due to pigment loss. He is currently studying the etiology and cell biology of the disease. Boissy received an award plaque at the Society for Investigative Dermatology meeting this month in Montreal. The achievement award is one of a series of ASA awards recognizing outstanding work that brings significant improvement in the treatment available to people suffering from specific skin disorders. Boissy, who also serves as the director of basic science research at the College of Medicine, has published over 100 scientific papers and 30 review articles and book chapters and has helped edit a book titled “The Pigmentary System: Physiology and Pathophysiology.” He is the past secretary/treasurer of the PanAmerican Society for Pigment Cell Research and is currently the chair of the National Vitiligo Foundation.
Congratulations to Ray Boissy!